Absci stock reaction to ABS-201 trial update and earnings

Absci (ABSI) drew fresh attention after releasing interim Phase 1 data for ABS-201 and reporting second quarter results, giving you new information on both its clinical pipeline and current financial profile.

Absci’s 1-day share price return of 4.44% and 7-day share price return of 10.97% around the ABS-201 update and earnings sit against a 30-day share price decline of 11.23%, alongside a strong 90-day share price return of 77.55% and very large 1-year total shareholder return. Together, these figures indicate that momentum has recently been building despite short-term swings.

If Absci’s recent move has you looking at other healthcare AI opportunities, it could be a useful moment to scan 43 healthcare AI stocks

Absci’s sharp longer term gains around ABS-201 sit next to recent volatility and ongoing losses. Is the latest swing a cleaner read on the underlying drug pipeline and partnerships, or more about changing risk appetite around the stock?

Most Popular Narrative: 32% Undervalued

The most followed narrative puts Absci’s fair value at $13.78 per share, compared with the last close of $9.41, and ties that gap directly to ABS-201 and aggressive growth assumptions.

Advancement of ABS-201 toward two proof of concept readouts in androgenetic alopecia and endometriosis over the next 24 months is described as positioning Absci to convert large underpenetrated markets into meaningful revenue growth and improved earnings power.

Read the complete narrative. Read the complete narrative.

Want to see what is behind that higher fair value for Absci? The narrative leans on rapid revenue expansion, margin improvement and a very rich future earnings multiple. Curious how those ingredients are combined into today’s $13.78 figure?

Result: Fair Value of $13.78 (UNDERVALUED)

However, the Absci story still hinges on ABS-201 clearing early proof of concept and on the company securing meaningful AI and pipeline partnerships, which both remain uncertain.

Another View on Absci’s valuation

The analyst narrative points to Absci trading below a $13.78 fair value, with potential tied to ABS-201 and rapid growth assumptions. On a simple P/B multiple, however, the stock appears expensive at 9.3x compared with 9.1x for peers and 2.5x for the wider US Biotechs industry. That premium leaves less room for error if ABS-201 or the AI platform faces setbacks, so how comfortable are you with this valuation?

To see how those balance sheet based metrics compare in more detail, and what they imply for potential upside or downside, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around Absci leave you unsure, move quickly to review the underlying data and form your own view using 1 key reward and 4 important warning signs

Looking for more investment ideas beyond Absci?

If Absci has sharpened your appetite for opportunities, do not stop here. Broaden your watchlist now so you are not catching up after the next big move.

• Target potential mispricing by scanning companies that screen as quality and are currently out of favour using 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that offer reliable cash returns through the 8 dividend fortresses.
• Reduce portfolio stress by focusing on companies with steadier risk profiles highlighted in the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.